Cristina Mezzanotte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cristina Mezzanotte has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Paladini
Postgraduate School in Internal Medicine, Dipartimento di Medicina Interna, Ospedali Riuniti di Ancona and Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy
1 shared publication - Eleonora Longhi
Postgraduate School in Clinical Pathology and Clinical Biochemistry, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy
1 shared publication - Gianluca Moroncini
Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy
1 shared publication - Maria Giovanna Danieli
Postgraduate School of Allergy and Clinical Immunology, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, via Tronto 10/A, 60126 Ancona, Italy
1 shared publication - Mario Andrea Piga
National PhD Course in Precision Medicine in Rare Diseases University of Palermo Palermo Italy
1 shared publication - Yehuda Shoenfeld
Medical School, Reichman University, Herzliya 4610101, Israel
1 shared publication
Latest Publications
- Open Access
- 16 September 2021
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 94 (5) , e13101
Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.
- 16 September 2021
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 94 (5) , e13101
Open AccessIntravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.